Daiichi Sankyo
Dalal Nesheiwat is an accomplished professional in the pharmaceutical industry, currently serving as Vice President and Global Head of Clinical Science at Daiichi Sankyo US since March 2022, focusing on R&D in oncology and hematology. Prior experience includes roles as Adjunct Faculty at LIU Brooklyn, Executive Director of Hematology Global Medical Affairs at Bristol Myers Squibb, and Senior Director at Celgene, where key contributions involved leadership in lymphoma and hematology developments. Dalal has also held significant positions at KYOWA KIRIN and Novartis, with a strong background in clinical development and regulatory submissions. Dalal earned a PharmD degree from Rutgers University.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.